Mycobacterium Haemophilum Follow-up

Updated: Oct 07, 2015
  • Author: Natalie C Klein, MD, PhD; Chief Editor: Mark R Wallace, MD, FACP, FIDSA  more...
  • Print

Further Outpatient Care

Patients require close outpatient follow-up care to document response to therapy (eg, every 2-4 wk). Length of therapy is prolonged in immunosuppressed patients, and patients with irreversible immunosuppression may require life-long suppressive therapy. Relapses have occurred in patients with AIDS who were on suppressive therapy. Whether patients on highly active antiretroviral therapy (HAART) can stop therapy if they have a good HAART response is unknown.

Discuss adherence to medications extensively with the patient to avoid development of resistance.


Further Inpatient Care

M haemophilum infection is diagnosed in many immunosuppressed patients who are hospitalized.

Treatment can be started or continued on an outpatient basis in most patients.



Prognosis for children with localized lymphadenitis is good.

In adults, the outcome is determined by their immune function.

In severely immunosuppressed patients, disease may require long-term therapy. Despite maintenance therapy, infection may persist or recur.


Patient Education

Adherence to medication is of utmost importance to prevent resistance.

Instruct patients to list all medications to avoid drug interactions.

Rifampin and rifabutin may interfere with contraceptives and numerous other medications, especially HIV-related therapy.